grepcent public filings, reorganized for comparison

Hims & Hers Health, Inc. (HIMS)

CIK: 0001773751. SIC: 8011 Services-Offices & Clinics of Doctors of Medicine. Latest 10-K as of: 2026-02-23.

SIC breadcrumb: Services > SIC Major Group 80 > SIC 8011 Services-Offices & Clinics of Doctors of Medicine

SEC company page: https://www.sec.gov/edgar/browse/?CIK=1773751. Latest filing source: 0001773751-26-000022.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-23 · accession 0001773751-26-000022 · source: SEC companyfacts

Revenue
2,347,637,000 USD verified
Net income
128,365,000 USD verified
Assets
2,154,705,000 USD verified
Free cash flow
57,406,000 USD computed
Net margin
5.47% computed
Operating margin
4.50% computed
Revenue YoY
+59.00% computed
ROE
23.73% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

HIMS ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 80; per-ratio N printed.HIMS ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 80; per-ratio N printed.RatioHIMSPeer medianPercentileNNet margin5.5%3.2%6456Operating margin4.5%5.5%4851Revenue growth59.0%11.8%9857FCF margin2.4%5.4%2848ROE23.7%7.9%9053ROA6.0%2.8%6858Liabilities / equity2.981.137754Current ratio1.901.636358

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 80 SIC Major Group 80, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue2,347,637,000USD20252026-02-23
Net income128,365,000USD20252026-02-23
Assets2,154,705,000USD20252026-02-23

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-23. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001773751.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric20182019202020212022202320242025
Revenue82,558,000148,757,000271,878,000526,916,000872,000,0001,476,514,0002,347,637,000
Net income-72,064,000-18,114,000-107,659,000-65,678,000-23,546,000126,038,000128,365,000
Operating income-74,414,000-15,144,000-115,042,000-68,697,000-29,453,00061,903,000105,613,000
Gross profit44,605,000109,450,000204,494,000408,722,000714,949,0001,173,135,0001,733,378,000
Diluted EPS-2.07-0.51-0.58-0.32-0.110.530.51
Operating cash flow-74,867,000-2,479,000-34,412,000-26,531,00073,483,000251,084,000300,006,000
Capital expenditures7,200,00026,500,00052,800,000242,600,000
Share buybacks0.000.000.000.001,999,00083,039,00089,960,000
Assets204,765,183118,697,000420,585,000366,341,000441,186,000707,539,0002,154,705,000
Liabilities8,173,14415,609,00085,966,00054,600,00097,157,000230,823,0001,613,777,000
Stockholders' equity-71,357,000-139,793,000-146,874,000334,619,000311,741,000344,029,000476,716,000540,928,000
Cash and cash equivalents1,510,34127,344,00071,784,00046,772,00096,663,000220,584,000228,616,000
Free cash flow-33,731,00046,983,000198,284,00057,406,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric20182019202020212022202320242025
Net margin-87.29%-12.18%-39.60%-12.46%-2.70%8.54%5.47%
Operating margin-90.14%-10.18%-42.31%-13.04%-3.38%4.19%4.50%
Return on equity-32.17%-21.07%-6.84%26.44%23.73%
Return on assets-35.19%-15.26%-25.60%-17.93%-5.34%17.81%5.96%
Liabilities / equity0.260.180.280.482.98
Current ratio1.697.433.414.523.001.791.90

Industry Peer Context

Each number-line places HIMS against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

HIMS Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8011; peer count 6.HIMS Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8011; peer count 6.6 SIC peersMin -12.1%Median -1.1%Max 29.4%HIMS 5.5%

Operating margin peer context

HIMS Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8011; peer count 6.HIMS Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8011; peer count 6.6 SIC peersMin -10.4%Median -5.6%Max 38.9%HIMS 4.5%

ROE peer context

HIMS ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8011; peer count 5.HIMS ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8011; peer count 5.5 SIC peersMin -14.5%Median 20.5%Max 62.0%HIMS 23.7%

ROA peer context

HIMS ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8011; peer count 6.HIMS ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8011; peer count 6.6 SIC peersMin -36.8%Median -0.1%Max 20.4%HIMS 6.0%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Income statement bridge from reported figures

HIMS FY2025 income statement bridge from reported figures.HIMS FY2025 income statement bridge from reported figures.HIMS income bridgeFY2025: revenue to net incomeSource: SEC companyfacts FY2025.Income statement bridgeReported amount$0.0B$2.0B$4.0B$2.3BRevenue-$614.3MCost$1.7BGross-$1.6BOpEx$105.6MOperating+$22.8MOther/tax$128.4MNet income

Figure provenance: SEC companyfacts FY 2025. Revenue: accession 0001773751-26-000022; concept RevenueFromContractWithCustomerExcludingAssessedTax; source concepts us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | Gross profit: accession 0001773751-26-000022; concept GrossProfit; source concepts us-gaap:GrossProfit | Operating income: accession 0001773751-26-000022; concept OperatingIncomeLoss; source concepts us-gaap:OperatingIncomeLoss | Net income: accession 0001773751-26-000022; concept NetIncomeLoss; source concepts us-gaap:NetIncomeLoss

Free cash flow = operating cash flow - capital expenditures

HIMS FY2025 free cash flow bridge from reported figures.HIMS FY2025 free cash flow bridge from reported figures.HIMS free cash flow bridgeFY2025: operating cash flow less capital expendituresSource: SEC companyfacts FY2025.Free cash flow bridgeReported amount$0.0B$250.0M$500.0M$300.0MOperating cash flow-$242.6MCapex$57.4MFree cash flow

Figure provenance: SEC companyfacts FY 2025. Operating cash flow: accession 0001773751-26-000022; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0001773751-26-000022; concept PaymentsToAcquireProductiveAssets; source concepts us-gaap:PaymentsToAcquireProductiveAssets | Free cash flow: accession 0001773751-26-000022; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquireProductiveAssets; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquireProductiveAssets

Financial Charts

HIMS revenue, last 5 periods. Source: SEC companyfacts FY2025.HIMS revenue, last 5 periods. Source: SEC companyfacts FY2025.HIMS RevenueLatest point: FY2025 = $2.3BSource: SEC companyfacts FY2025.Fiscal yearReported revenue$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

HIMS net income, last 5 periods. Source: SEC companyfacts FY2025.HIMS net income, last 5 periods. Source: SEC companyfacts FY2025.HIMS Net incomeLatest point: FY2025 = $128.4MSource: SEC companyfacts FY2025.Fiscal yearNet income-$250.0M$0.0B$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

HIMS operating income, last 5 periods. Source: SEC companyfacts FY2025.HIMS operating income, last 5 periods. Source: SEC companyfacts FY2025.HIMS Operating incomeLatest point: FY2025 = $105.6MSource: SEC companyfacts FY2025.Fiscal yearOperating income-$250.0M$0.0B$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

HIMS gross profit, last 5 periods. Source: SEC companyfacts FY2025.HIMS gross profit, last 5 periods. Source: SEC companyfacts FY2025.HIMS Gross profitLatest point: FY2025 = $1.7BSource: SEC companyfacts FY2025.Fiscal yearGross profit$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: GrossProfit. Source concepts: us-gaap:GrossProfit.

HIMS diluted eps, last 5 periods. Source: SEC companyfacts FY2025.HIMS diluted eps, last 5 periods. Source: SEC companyfacts FY2025.HIMS Diluted EPSLatest point: FY2025 = $0.51/shareSource: SEC companyfacts FY2025.Fiscal yearDiluted EPS (USD/share)-$1.00/share$0.00/share$1.00/shareFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

HIMS operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.HIMS operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.HIMS Operating cash flowLatest point: FY2025 = $300.0MSource: SEC companyfacts FY2025.Fiscal yearOperating cash flow-$250.0M$0.0B$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

HIMS capital expenditures, last 4 periods. Source: SEC companyfacts FY2025.HIMS capital expenditures, last 4 periods. Source: SEC companyfacts FY2025.HIMS Capital expendituresLatest point: FY2025 = $242.6MSource: SEC companyfacts FY2025.Fiscal yearCapital expenditures$0.0B$125.0M$250.0M$7.2MFY2022$26.5MFY2023$52.8MFY2024$242.6MFY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: PaymentsToAcquireProductiveAssets. Source concepts: us-gaap:PaymentsToAcquireProductiveAssets.

HIMS share buybacks, last 5 periods. Source: SEC companyfacts FY2025.HIMS share buybacks, last 5 periods. Source: SEC companyfacts FY2025.HIMS Share buybacksLatest point: FY2025 = $90.0MSource: SEC companyfacts FY2025.Fiscal yearShare buybacks$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: PaymentsForRepurchaseOfCommonStock. Source concepts: us-gaap:PaymentsForRepurchaseOfCommonStock.

HIMS assets, last 5 periods. Source: SEC companyfacts FY2025.HIMS assets, last 5 periods. Source: SEC companyfacts FY2025.HIMS AssetsLatest point: FY2025 = $2.2BSource: SEC companyfacts FY2025.Fiscal yearAssets$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: Assets. Source concepts: us-gaap:Assets.

HIMS liabilities, last 5 periods. Source: SEC companyfacts FY2025.HIMS liabilities, last 5 periods. Source: SEC companyfacts FY2025.HIMS LiabilitiesLatest point: FY2025 = $1.6BSource: SEC companyfacts FY2025.Fiscal yearLiabilities$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

HIMS stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.HIMS stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.HIMS Stockholders' equityLatest point: FY2025 = $540.9MSource: SEC companyfacts FY2025.Fiscal yearStockholders' equity$0.0B$375.0M$750.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

HIMS cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.HIMS cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.HIMS Cash and cash equivalentsLatest point: FY2025 = $228.6MSource: SEC companyfacts FY2025.Fiscal yearCash and cash equivalents$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

HIMS free cash flow, last 4 periods. Source: SEC companyfacts FY2025.HIMS free cash flow, last 4 periods. Source: SEC companyfacts FY2025.HIMS Free cash flowLatest point: FY2025 = $57.4MSource: SEC companyfacts FY2025.Fiscal yearFree cash flow-$250.0M$0.0B$500.0MFY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001773751-26-000022; filed 2026-02-23. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquireProductiveAssets. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquireProductiveAssets.

As-reported value updates

9 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

View the filing-by-filing ledger →

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-10. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001773751.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2022-Q32022-09-30-0.09reported discrete quarter
2023-Q12023-03-31-0.05reported discrete quarter
2023-Q22023-06-30-0.03reported discrete quarter
2023-Q32023-06-30-7,157,000reported discrete quarter
2023-Q32023-09-30226,699,000-0.04reported discrete quarter
2023-Q42023-12-31246,619,0001,245,000derived Q4 = FY annual - nine-month YTD
2024-Q12024-03-31278,171,00011,128,0000.05reported discrete quarter
2024-Q22024-03-3111,128,000reported discrete quarter
2024-Q22024-06-30315,648,0000.06reported discrete quarter
2024-Q32024-06-3013,297,000reported discrete quarter
2024-Q32024-09-30401,556,0000.32reported discrete quarter
2024-Q42024-12-31481,139,00026,025,000derived Q4 = FY annual - nine-month YTD
2025-Q12025-03-31586,010,00049,485,0000.20reported discrete quarter
2025-Q22025-03-3149,485,000reported discrete quarter
2025-Q22025-06-30544,833,0000.17reported discrete quarter
2025-Q32025-06-3042,505,000reported discrete quarter
2025-Q32025-09-30598,976,0000.06reported discrete quarter
2025-Q42025-12-31617,818,00020,601,000derived Q4 = FY annual - nine-month YTD
2026-Q12026-03-31608,104,000-92,115,000-0.40reported discrete quarter
2026-Q22026-03-31-92,115,000reported discrete quarter
2026-Q22026-06-30753,214,000-0.37reported discrete quarter

Quarterly Charts

HIMS quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.HIMS quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.HIMS Quarterly RevenueLatest point: 2026-Q2 = $753.2MSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Revenue$0.0B$500.0M$1.0B2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001773751-26-000163; filed 2026-08-10. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

HIMS quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.HIMS quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.HIMS Quarterly Net incomeLatest point: 2026-Q2 = -$92.1MSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Net income-$250.0M$0.0B$250.0M2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001773751-26-000076; filed 2026-05-11. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

HIMS quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.HIMS quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.HIMS Quarterly Diluted EPSLatest point: 2026-Q2 = -$0.37/shareSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Diluted EPS (USD/share)-$0.50/share$0.00/share$0.50/share2022-Q32023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001773751-26-000163; filed 2026-08-10. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read HIMS's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read HIMS's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0001773751-26-000163.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-08-10. Report date: 2026-06-30.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)

The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our Form 10-K for the year ended December 31, 2025 (our “2025 Annual Report”), including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Item 7 of Part II of our 2025 Annual Report and the accompanying unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q. Our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should not rely on forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we do not intend to update any of these forward-looking statements after the date hereof or to conform these statements to actual results or revised expectations. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the section titled “Risk Factors” in Item 1A of Part II of this Quarterly Report on Form 10-Q.

Unless otherwise indicated or the context otherwise requires, references in this discussion and analysis to “we,” “us,” “our,” the “Company,” and “Hims & Hers” refer to Hims & Hers Health, Inc. and its subsidiaries and variable interest entities.

38

Table of Contents

Overview

Hims & Hers is a consumer-first platform transforming the way customers fulfill their health and wellness needs. Our mission is to help the world feel great through the power of better health. We believe that we have the technical infrastructure, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized, digital, accessible format. The Hims & Hers platforms (collectively, our “platform”) include access to a highly-qualified and technologically-capable provider network, a clinically-focused electronic medical records system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Our digital platform enables access to treatments for a broad range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Prescriptions are fulfilled online through licensed pharmacies, making accessing treatments simple, affordable, and straightforward. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness.

In addition, we offer access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Our products and services are available for purchase directly by customers on our websites and mobile applications. Additionally, Hims & Hers non-prescription products can be found in tens of thousands of top retail locations in the United States.

Revenue and Key Business Metrics

Our management monitors United States Revenue and Rest of the World Revenue (both defined below) to track our total revenue generation. We also monitor the additional key business metrics set forth below to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. Increases or decreases in these key business metrics may not correspond with increases or decreases in our revenue. We continually and strategically review our key business metrics to ensure that they are helpful in managing or monitoring the performance of our business as it grows, which may result in changes in our key business metrics over time. Our management primarily uses the Subscribers and Monthly Revenue per Average Subscriber metric, each as defined below, to manage and monitor the performance of our business.

The limitations our key business metrics have as an analytical tool include: (i) they might not accurately predict our future financial results pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”); and (ii) other companies, including companies in our industry, may calculate our key business metrics or similarly titled measures differently, which reduces their usefulness as comparative measures.

Our consolidated revenue primarily comprises online sales of health and wellness products through our websites and mobile applications, including prescription and non-prescription products, as well as services, primarily consisting of medical consultation services, membership-based access, post-consultation service support, and delivery of laboratory testing results, as applicable. Our online sales are net of refunds, credits, and chargebacks, and include revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. A substantial majority of our online sales are subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them. This revenue also includes sales from customers who have made one-time purchases. Additionally, in the United States, we offer a range of health and wellness products through wholesale partners as a way of generating brand awareness with new customers in physical environments and on third-party platforms, with such revenue not considered material to our business.

Brief descriptions of our key business metrics are provided below.

“United States Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located inside of the United States.

“Rest of the World Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located outside of the United States.

39

Table of Contents

“Subscribers” are customers who have one or more “Subscriptions” pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services. Customers who have made one-time purchases are not considered Subscribers.

“Monthly Revenue per Average Subscriber” is defined as total revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

The table below provides a breakdown of total revenue between United States Revenue and Rest of the World Revenue for the three and six months ended June 30, 2026 and 2025, as well as key business metrics that we believe drive total revenue (i.e., Subscribers and Monthly Revenue per Average Subscriber) and the change and percentage change between such periods (in thousands, except for Monthly Revenue per Average Subscriber and percentage change):

Three Months Ended June 30,Six Months Ended June 30,
20262025Change% Change20262025Change% Change
United States Revenue$621,830$537,286$84,54416%$1,151,739$1,115,978$35,7613%
Rest of the World Revenue131,3847,547123,8371,641%209,57914,865194,7141,310%
Total revenue$753,214$544,833$208,38138%$1,361,318$1,130,843$230,47520%
Subscribers (end of period)2,8912,43945219%2,8912,43945219%
Monthly Revenue per Average Subscriber$92$76$1621%$84$81$34%

We generated $621.8 million in United States Revenue for the three months ended June 30, 2026, an increase of $84.5 million, or 16%, as compared to $537.3 million for the three months ended June 30, 2025. We generated $1,151.7 million in United States Revenue for the six months ended June 30, 2026, an increase of $35.8 million, or 3%, as compared to $1,116.0 million for the six months ended June 30, 2025. The increases in United States Revenue for the three and six months ended June 30, 2026 were primarily driven by growth in our Hers brand as a result of an expanded assortment of branded weight loss offerings, partially offset by the impact of a change in the timing of revenue recognition for certain of our weight loss offerings, inclusive of our Hers brand, as a result of a shift to shorter shipping cadences. During the three months ended June 30, 2026, our Hers brand represented over 40% of United States Revenue, compared to representing approximately 35% of United States Revenue for the three months ended June 30, 2025. During each of the six months ended June 30, 2026 and 2025, our Hers brand represented approximately 40% of United States Revenue. Uptake of the Hers brand is primarily driven by our weight loss and dermatology offerings. During the three and six months ended June 30, 2026, a majority of our total United States Revenue came from non-glucagon-like peptide-1 receptor agonist (“GLP-1”) offerings. United States Revenue can fluctuate on a period-to-period basis due to various factors, including launches of new product offerings, the success of our marketing campaigns, product shipping cadences, and pricing decisions impacting customer uptake of our offerings, as well as product availability and the regulatory landscape impacting our offerings.

We generated $131.4 million in Rest of the World Revenue for the three months ended June 30, 2026, an increase of $123.8 million, or 1,641%, as compared to $7.5 million for the three months ended June 30, 2025. We generated $209.6 million in Rest of the World Revenue for the six months ended June 30, 2026, an increase of $194.7 million, or 1,310%, as compared to $14.9 million for the six months ended June 30, 2025. Growth in Rest of the World Revenue was primarily driven by the geographic expansion from our recent acquisitions, including our acquisition of Eucalyptus, which closed in the last month of the second quarter of 2026. Rest of the World Revenue can fluctuate on a period-to-period basis due to various factors, including those r

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0001773751-26-000022. The complete FY 2025 MD&A is published at /company/HIMS/mda/fy2025/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high. Filing date: 2026-02-23. Report date: 2025-12-31.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and accompanying notes included in Part II, Item 8 of this Form 10-K. This section of the Form 10-K generally discusses 2025 and 2024 items and year-to-year comparisons between 2025 and 2024. Discussions of 2023 items and year-to-year comparisons between 2024 and 2023 are not included in this Form 10-K, and can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2024. Our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should not rely on forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we do not intend to update any of these forward-looking statements after the date hereof or to conform these statements to actual results or revised expectations. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the section entitled “Risk Factors” in this Form 10-K.

Unless otherwise indicated or the context otherwise requires, references in this discussion and analysis to “we,” “us,” “our,” the “Company,” and “Hims & Hers” refer to Hims & Hers Health, Inc. and its subsidiaries and variable interest entities.

Overview

Hims & Hers is a consumer-first platform transforming the way customers fulfill their health and wellness needs. Our mission is to help the world feel great through the power of better health. We believe that we have the technical infrastructure, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized,

64

Table of Contents

digital, accessible format. The Hims & Hers platforms (collectively, our “platform”) include access to a highly-qualified and technologically-capable provider network, a clinically-focused electronic medical records system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Our digital platform enables access to treatments for a broad range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Prescriptions are fulfilled online through licensed pharmacies, making accessing treatments simple, affordable, and straightforward. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness.

In addition, we offer access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Our products and services are available for purchase directly by customers on our websites and mobile applications. Additionally, Hims & Hers non-prescription products can be found in tens of thousands of top retail locations in the United States.

Recent Developments

In February 2026, Horizon BidCo Pty Ltd ACN 694 778 375 (the “Purchaser”), an Australian proprietary company and wholly-owned subsidiary of our company, entered into a Securities Sale Deed (the “Deed”) by and among our company, Hims, Inc., the Purchaser and the sellers named therein, to purchase all of the issued capital of EUC Management Pty Ltd ACN 631 013 860 (d/b/a Eucalyptus) (“Eucalyptus”), an Australia-based digital health company that operates in Australia, the United Kingdom, Germany, Canada, and Japan. The aggregate total consideration of the transaction is up to $1.15 billion, subject to certain adjustments set forth in the Deed (the “Proposed Acquisition”). We entered into the Proposed Acquisition to expand into Australia and Japan and deepen our presence in the United Kingdom, Germany, and Canada. The upfront cash consideration payable at closing is approximately $240 million, not including certain closing adjustments as set forth in the Deed. Deferred payments totaling an additional amount of approximately $710 million, not including certain closing adjustments as set forth in the Deed, are payable in six quarterly installments through the 18-month anniversary of the closing. A maximum additional amount of approximately $200 million in earn-out payments, not including certain closing adjustments as set forth in the Deed, are payable following the release of our results for each of fiscal years 2026, 2027, and 2028, respectively, upon Eucalyptus achieving certain revenue and adjusted EBITDA targets. We have the option to settle approximately 60% of the deferred and earn-out payments in cash or our Class A common stock, at our election. The Proposed Acquisition is subject to customary closing conditions and is expected to close in mid-2026.

Revenue and Key Business Metrics

Our management monitors certain financial results to track our total revenue generation. Historically, we have disaggregated our total revenue between Online Revenue and Wholesale Revenue (both defined below). During 2025, as a result of completed acquisitions, we launched operations in the European Union and Canada, and deepened our presence in the United Kingdom. We expect to continue to expand internationally, including in connection with our Proposed Acquisition of Eucalyptus. As a result, beginning with this Annual Report on Form 10-K, we are now disaggregating our total revenue between United States Revenue and Rest of the World Revenue (both defined below). Additionally, Online Revenue and Wholesale Revenue have become a less relevant disaggregation of our total revenue, and we anticipate no longer reporting these financial results beginning with the three months ending March 31, 2026. We also monitor the additional key business metrics set forth below to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. Increases or decreases in these key business metrics may not correspond with increases or decreases in our revenue. We continually and strategically review our key business metrics to ensure that they are helpful in managing or monitoring the performance of our business as it grows, which may result in changes in our key business metrics over time. As an example, Monthly Online Revenue per Average Subscriber (as defined below) has become less relevant for our business. We anticipate no longer reporting this metric beginning with the three months ending March 31, 2026, and are instead reporting Monthly Revenue per Average Subscriber, as defined below, beginning with this Annual Report on Form 10-K.

The limitations our key business metrics have as an analytical tool include: (i) they might not accurately predict our future financial results pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”); and (ii) other companies, including companies in our industry, may calculate our key business metrics or similarly titled measures differently, which reduces their usefulness as comparative measures.

65

Table of Contents

Brief descriptions of our key business metrics are provided below.

“United States Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located inside of the United States.

“Rest of the World Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located outside of the United States.

“Online Revenue” represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them. Online Revenue also includes sales from customers who have made one-time purchases.

“Wholesale Revenue” represents non-prescription product sales to retailers through wholesale purchasing agreements. Wholesale Revenue also includes non-prescription product sales to third-party platforms through consignment arrangements. In addition to being revenue generative and profitable, wholesale partnerships and consignment arrangements have the added benefit of generating brand awareness with new customers in physical environments and on third-party platforms.

“Subscribers” are customers who have one or more “Subscriptions” pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services. Customers who have made one-time purchases are not considered Subscribers.

“Monthly Revenue per Average Subscriber” is defined as total revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

“Monthly Online Revenue per Average Subscriber” is defined as Online Revenue divided by Average Subscribers, which amount is then further divided by the number of months in a period.

66

Table of Contents

The table below provides a breakdown of total revenue between (i) United States Revenue and Rest of the World Revenue and (ii) Online Revenue and Wholesale Revenue, for the years ended December 31, 2025, 2024, and 2023, as well as key metrics that drive total revenue and Online Revenue (i.e., Subscribers, Monthly Revenue per Average Subscriber, and Monthly Online Revenue per Average Subscriber) and the dollar and percentage change between such periods (in thousands, except for Monthly Revenue per Average Subscriber and Monthly Online Revenue per Average Subscriber):

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

Macro cross-references for HIMS

Indicators mapped to this company's SIC classification (industry 8011 Services-Offices & Clinics of Doctors of Medicine) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: US labor market, Growth & output, Government finances, Sector employment.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/HIMS.md · JSON record: /company/HIMS.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt